March 30, 2015
Use of a single self-expanding stent up to 20 cm in length in long femoropopliteal lesions was associated with acceptable stent patency and freedom from clinically driven target lesion revascularization and a low rate of stent fracture at 3 years, researchers for the DURABILITY II trial reported in Catheterization and Cardiovascular Interventions.
Researchers evaluated the long-term safety and efficacy of the single self-expanding peripheral stent system (EverFlex, Covidien) in patients with atherosclerotic disease of the superficial femoral and proximal popliteal arteries. The study included 287 patients (mean age, 68 years; 66% men; mean lesion length, 8.9 cm). Of those, the researchers reported 3-year follow-up data on 220 patients.